Videos

Prime Therapeutics projects that by 2017, the cost of specialty pharmaceuticals will be half the cost of all pharmacy claims. Therefore, noted Duane Barnes, senior vice president, consumer delivery at Prime Therapeutics, it is important for a PBM to align its medical and pharmacy policies.

Debbie Stern of Rxperts highlights the various "unknowns" surrounding the potential cost savings of biosimilar products, such as interchangeability and the possible need for additional clinical trials.

Specialty pharmacies can minimize "cost to treat" by identifying which specialty drugs have dose optimization opportunities, noted Michael Einodshofer, RPh, MBA, director of utilization management, Walgreens, at the 2013 PBMI Drug Benefit Conference.

Bill Sullivan, executive director of SPAARx, describes how his organization's definition of "specialty pharmacy" compares with other entities' definitions.

Philip R. Schauer, MD, discusses the need for accountable care organizations to recognize obesity as a disease and offer treatment for it.

Jennifer Athay-Adams, PharmD, discusses how the payment model of accountable care organizations (ACOs) differs from that of traditional HMOs.

Debbie Stern of Rxperts discusses the findings from the EMD Serono Specialty Digest, 9th Edition, and the use of specialty drug tiers by payers.

Pharmacy accreditation is starting to gain some recognition, noted Quintin Jessee, RPh, DPh, D2 Pharma Consulting in this video shot at the 2013 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.

Adam J. Fein of Drug Channels explains the reasons drug manufacturers choose limited distribution channels.

Michael Einodshofer, director, utilization management, Walgreens, describes how contractual methodologies and cost differences across various sites of service can influence how a specialty drug is reimbursed under the medical benefit.

Debbie Stern, RPh, president of Rxperts, explains why a high entry cost for a specialty drug may dissuade a patient from filling and staying adherent to his or her prescription.

Adam Fein describes the way in which the sequester will affect physician reimbursement for specialty drugs.

Michael Einodshofer of Walgreens discusses the challenges associated with moving specialty into retail in this video shot at PBMI's Drug Benefit Conference 2013.

Rebecca P. Snead, RPh, of the National Alliance of State Pharmacy Associations, discusses the movement for pharmacist provider status.

A pharmacy in Lake City, Tennessee, has been operating for 80 years under the management of several generations of a single family.

Adam J. Fein describes how the 340B program is being exploited by many hospital systems due to a lack of oversight by government agencies.

Einodshofer explains how the costs associated with one specialty patient's treatment can have the same financial footprint as an entire population of patients. Video from PBMI's Drug Benefit Conference 2013.

In this video from the 2013 Armada Specialty Pharmacy Summit in Las Vegas, Nevada, Adam J. Fein of Pembroke Consulting Inc and Drug Channels discusses the boom in new specialty pharmacy trade associations and describes the impact that competition amongst specialty pharmacy providers could have on the industry.

Troy Trygstad, PharmD, PhD, MBA, co-editor of the Directions in Pharmacy supplements, discusses the evolving health care landscape and how pharmacists can navigate it.

Colin Cooke, MD, discusses the role of the Affordable Care Act in expanding insurance coverage and in the formation of accountable care organizations.

Troy Trygstad, PharmD, PhD, MBA, discusses a flexible patient-centric approach to health care.

Timothy Ulbrich, PharmD, discusses the role of the pharmacist and how pharmacists are key to addressing our nation's medication crisis.

Troy Trygstad, PharmD, PhD, MBA, discusses emerging technology trends and how investments in technology will change health care.

Morgan Pharmacy in Washington, DC, has managed to keep its doors open for more than 100 years.

Troy Trygstad, PharmD, PhD, MBA, discusses the importance of the value-based model in health care and the perils and opportunities it poses to pharmacists.

In this video, executives from AstraZeneca and MedImmune explain why access to innovation in the development of biologics is so important.

Patrick Gleason, PharmD, BCPS, FCCP, director of Health Outcomes at Prime Therapeutics, discusses the value of pharmacogenomic testing and the factors that influence whether a health plan or PBM will reimburse for the use of that test.

Patrick Gleason, PharmD, BCPS, FCCP, director of health outcomes for Prime Therapeutics, explains how split-fill programs can help reduce waste for expensive specialty medications.

Jyoti Bhagia, MD, discusses use of a rating scale in diagnosing and treating patients with ADHD.

William A. Scott, MD, addresses the question of whether children who are initiating use of ADHD medication need to have an EKG.